» Articles » PMID: 10426126

Increased C-myc Oncogene Expression in Ewing's Sarcoma: Correlation with Ki67 Proliferation Index

Overview
Journal Tumori
Publisher Sage Publications
Specialty Oncology
Date 1999 Jul 30
PMID 10426126
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Aims And Background: Ewing's sarcoma is a highly malignant musculoskeletal tumor composed of small round cells. Although important results have been achieved with surgery associated with chemotherapy, recurrent disease is still a major problem. In order to define new prognostic factors useful for therapeutic decision-making, we conducted a study on 38 Ewing's sarcoma samples in which c-myc oncogene expression and Ki67 proliferation index were correlated with clinical outcome.

Methods And Study Design: Nineteen patients developed metastases during follow-up and 10 of these patients died. C-myc and Ki67 protein expression was evaluated by immunohistochemistry performed on 5 microm formalin-fixed and paraffin-embedded sections, while the c-myc mRNA transcript was localized using in situ hybridization.

Results: A statistically positive correlation was found between c-myc protein and Ki67 (P = 0.001) and c-myc mRNA and Ki67 expression (P = 0.047). The 38 patients were divided into two groups using as the cutoff 50% of Ki67-positive cells. The disease-free survival and overall survival estimates were 68% and 90%, respectively, in the group of patients with a percentage of Ki67-positive cells <50%, and 25% and 50%, respectively, in the group with a percentage of Ki67-positive cells > or = 50%. The difference between the survival curves was statistically significant (P <0.05 and P <0.01). Furthermore, relapsed patients had a high and uniform expression of c-myc protein and mRNA compared to disease-free patients.

Conclusion: These results suggest a possible role of the c-myc oncogene and Ki67 antigen in the malignant progression of Ewing's sarcoma.

Citing Articles

Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target.

Sias F, Zoroddu S, Migheli R, Bagella L Int J Mol Sci. 2025; 26(5).

PMID: 40076599 PMC: 11900228. DOI: 10.3390/ijms26051973.


Molecular mechanisms underpinning sarcomas and implications for current and future therapy.

Damerell V, Pepper M, Prince S Signal Transduct Target Ther. 2021; 6(1):246.

PMID: 34188019 PMC: 8241855. DOI: 10.1038/s41392-021-00647-8.


The c-Myc/AKT1/TBX3 Axis Is Important to Target in the Treatment of Embryonal Rhabdomyosarcoma.

Sims D, Maranyane H, Damerell V, Govender D, Isaacs A, Peres J Cancers (Basel). 2020; 12(2).

PMID: 32098189 PMC: 7072582. DOI: 10.3390/cancers12020501.


Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma.

Casey D, Lin T, Cheung N Front Oncol. 2019; 9:537.

PMID: 31275859 PMC: 6593481. DOI: 10.3389/fonc.2019.00537.


Super-enhancer-associated MEIS1 promotes transcriptional dysregulation in Ewing sarcoma in co-operation with EWS-FLI1.

Lin L, Huang M, Shi X, Mayakonda A, Hu K, Jiang Y Nucleic Acids Res. 2018; 47(3):1255-1267.

PMID: 30496486 PMC: 6379679. DOI: 10.1093/nar/gky1207.